Published in final edited form as:

Nat Struct Mol Biol. 2017 October ; 24(10): 825–833. doi:10.1038/nsmb.3466.

Guide-bound structures of an RNA-targeting A-cleaving CRISPR-Cas13a enzyme

Gavin J. Knott^{1,9}, Alexandra East-Seletsky^{1,9}, Joshua C. Cofsky¹, James M. Holton^{2,3,4}, Emeric Charles¹, Mitchell R. O'Connell^{1,5}, and Jennifer A. Doudna^{1,2,6,7,8,*}

¹Department of Molecular and Cell Biology, University of California, Berkeley, California, 94720, USA

²Molecular Biophysics & Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, USA

³Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, Menlo Park, USA

⁴Department of Biochemistry and Biophysics, University of California, San Francisco, USA

⁶Department of Chemistry, University of California, Berkeley, California, 94720, USA

⁷Howard Hughes Medical Institute, University of California, Berkeley, California 94720, USA

⁸Innovative Genomics Institute, University of California, Berkeley, California 94720, USA

Abstract

CRISPR adaptive immune systems protect bacteria from infections by deploying CRISPR RNA (crRNA)-guided enzymes to recognize and cut foreign nucleic acids. Type VI-A CRISPR-Cas systems include the Cas13a enzyme, an RNA-activated ribonuclease (RNase) capable of crRNA processing and single-stranded RNA degradation upon target transcript binding. Here we present the 2.0 Å resolution crystal structure of a crRNA-bound *L. bacterium* Cas13a (LbaCas13a), representing a recently discovered Cas13a enzyme subtype. This structure and accompanying biochemical experiments define for the first time the Cas13a catalytic residues that are directly responsible for crRNA maturation. In addition, the orientation of the foreign-derived target RNA-specifying sequence in the protein interior explains the conformational gating of Cas13a nuclease activation. These results describe how Cas13a enzymes generate functional crRNAs and how

*Correspondence should be addressed to J.A.D (doudna@berkeley.edu).

⁵Present address: Center for RNA Biology and Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA.

⁹These two authors contributed equally.

ONLINE CONTENT

The atomic coordinates and structure factors for the LbaCas13a-crRNA complexes have been deposited to the Protein Data Bank (PDB) under the accession codes 5W1H for LbaCas13a:crRNA complex (24-nt spacer), 5W1I for LbaCas13a:crRNA complex (20-nt spacer) and 5WLH for LbaCas13a(H328A):pre-crRNA complex (24-nt spacer).

AUTHOR CONTRIBUTIONS

G.J.K., A.E.-S., M.R.O. and J.A.D. designed the study. G.J.K., A.E.-S., J.C.C. and E.C. expressed and purified proteins. G.J.K. prepared and crystallized the Cas13a complexes with assistance from J.C.C., collected X-ray data, and determined the crystal structure with support from J.H. A.E.S. carried out biochemical assays with assistance from G.J.K. and J.C.C. G.J.K. drafted the manuscript, and all authors reviewed and edited the manuscript.

catalytic activity is blocked prior to target RNA recognition, with implications for both bacterial immunity and diagnostic applications.

INTRODUCTION

A repertoire of defensive mechanisms evolved to protect bacteria against phage and other mobile genetic elements¹. Unique among these mechanisms are CRISPR-Cas (clustered regularly interspaced short palindromic repeats, CRISPR-associated) adaptive immune systems, which use RNA-guided nucleases to direct cleavage of invading DNA or RNA^{2,3}. The programmability of DNA-targeting CRISPR-Cas enzymes has driven a revolution in technologies for gene editing, transcriptional control, and genomic imaging⁴⁻⁶. Similarly, RNA-targeting CRISPR-Cas systems offer the potential for RNA-programmed RNA detection and development as scaffolds for designer RNA binding proteins⁷⁻¹⁴.

Type VI-A RNA-targeting CRISPR-Cas systems are defined by the single effector protein Cas13a (formerly C2c2), which forms a target surveillance complex with a CRISPR RNA (crRNA). The crRNA, encoded by the genomic CRISPR locus, contains a defined 5' hairpin structure preceding a 3' foreign-derived variable region (or 3' spacer)^{8,15}. In Type VI-A CRISPR-Cas systems, Cas13a catalyzes maturation of the transcribed pre-crRNA using a metal ion-independent active site that has not been well defined^{10,16}. Once assembled with its mature crRNA, Cas13a is competent for foreign single-stranded RNA (ssRNA) target surveillance. Recognition of a spacer-complementary ssRNA transcript (ssRNA-activator) activates the HEPN (higher eukaryotes and prokaryotes nucleotide-binding) domains of the enzyme to create a composite general RNase active site^{8,16,17}, distinct from that responsible for crRNA maturation¹⁰. Across the Cas13a family, this composite HEPN active-site is functionally diverse, in terms of both nucleotide cleavage preference and turnover efficiency¹⁴. Two distinct subfamilies, named for their cleavage preference (adenosine (A)-cleaving or uridine (U)-cleaving), exist within the Cas13a protein family and can be harnessed in parallel for RNA detection¹⁴.

The molecular cues of Cas13a HEPN nuclease activation are unknown, limiting the development of Cas13a-based tools. Recent structural studies on the apo and binary complex of *Leptotrichia shahii* Cas13a established the HEPN domains form a surface exposed composite active site¹⁶. While an attractive possibility, multiplexed RNA detection from the two Cas13a subfamilies is limited by an incomplete mechanistic understanding of the different crRNA binding specificities and catalytic efficiencies, especially in light of substantial sequence divergence within the family¹⁴.

To determine the structural basis for the divergent activities of the A-cleaving Cas13a subfamily, we solved a 2.0 Å resolution crystal structure of *Lachnospiraceae bacterium* Cas13a (LbaCas13a). This structure and accompanying biochemical experiments revealed the active-site for pre-crRNA processing in the A-cleaving Cas13a subfamily. The structure also showed that LbaCas13a shields the spacer region of the crRNA from target hybridization, providing clues to the conformational rearrangement required to activate the HEPN nuclease for general RNase activity. Finally, structural comparisons to the previously modeled U-cleaving subfamily member, LshCas13a¹⁶, rationalize how these enzyme

subfamilies recognize unique sets of crRNAs that enable orthogonal RNA detection in complex mixtures. Together, these findings provide new insights into the mechanisms controlling crRNA generation by, and target RNA activation of, Cas13a.

RESULTS

Global architecture of LbaCas13a:crRNA complex

The Cas13a enzyme family depends on two distinct nuclease activities for biological function, yet neither nuclease active-site has been well described in terms of mechanism or conformational regulation. To further investigate the mechanisms of pre-crRNA processing and activator driven HEPN nuclease activity, we studied a divergent A-cleaving homolog, LbaCas13a, enabling comparisons to previously investigated U-cleaving subfamily members LshCas13a and *Leptotrichia buccalis* (Lbu) Cas13a (Fig. 1a). We determined the crystal structure of LbaCas13a (residues 1-1437) in complex with a mature crRNA to 2.0 Å resolution by native single-wavelength anomalous dispersion (SAD) (Fig. 1b–d; Table 1; Supplementary Fig. S1a). To obtain a mature crRNA for binary complex crystallization, LbaCas13a was incubated with a 60-nt pre-crRNA, allowing the enzyme to process the crRNA, before purifying the resulting complex (Supplementary Fig. S1b). The mature crRNA within the structure was resolved as 41 well-ordered nucleotides that includes the 28-nt 5′ direct repeat (henceforth referred to as the 5′ handle) (A(-28)-C(-1)) and 13 nucleotides of the 3′ spacer. Only the first 13 nucleotides (C(1)-G(13)) of the 3′ spacer are well-ordered within the crystal structure with the remaining 11 nucleotides G(14)-C(24) present, but disordered within the structure (Fig. 1b; Supplementary Fig. S1c).

LbaCas13a adopts a predominantly α-helical fold comprising six discrete domains that encase the crRNA to form an active surveillance complex (Fig. 1c, d). Consistent with other single-protein CRISPR effectors, its overall architecture is bi-lobed; the N-terminal domain (NTD) and the Helical-1 domain form the crRNA recognition (REC) lobe, and the HEPN1, Helical-2, Helical-3, and HEPN2 domains form the nuclease (NUC) lobe. The crRNA 5′ handle is bound by the REC lobe within a positively charged channel formed between the NTD and Helical-1 domains, while the spacer is channeled into a cavity formed within the NUC lobe (Fig. 1d; Supplementary Fig. 1c). The NUC lobe in turn encompasses two distinct structural domains, NUC1 and NUC2, that “sandwich” the targeting region of the crRNA into a planar orientation (Fig. 1d; Supplementary Fig. 1c). The NUC1 lobe contains the N-terminal half of HEPN1 (HEPN1-I), connected by a large α-helical domain, Helical-2. The NUC2 lobe comprises the C-terminal half of HEPN1 (HEPN1-II), Helical-3 and HEPN2 domains. The overall architecture of this A-cleaving Cas13a is related to the U-cleaving *Leptotrichia shahii* Cas13a (LshCas13a)¹⁶, with notable differences in the NTD and Helical-3 domain disposition (Supplementary Fig. S2).

Recognition of a compact and divergent crRNA handle

A hallmark of CRISPR interference complexes is highly specific and tight binding between effector proteins and their cognate crRNA^{18–22}. Multiple sequence alignment of the crRNA repeat across both Cas13a subfamilies suggests that the 5′ handle of Type VI-A CRISPR-Cas systems forms a conserved hairpin structure comprising a 5-nt base-paired stem, an 8–9

nt loop, and a 2-nt bulge within the stem (Fig. 2a)¹⁴. Previous work established that LbaCas13a can process and utilize crRNA handles from all A-cleaving subfamily members but cannot utilize crRNA handles from the related U-cleaving subfamily despite the similarity of their predicted structures (Fig. 2a)¹⁴. We wondered if our structure could inform us on the molecular basis for the restrictions on Cas13a subfamily crRNA exchangeability.

This structure of LbaCas13a revealed that the crRNA preference is determined by a combination of loop conformation and a divergent set of contacts between the 5' handle and Cas13a (Fig. 2b–f; Supplementary Fig. S3a). LbaCas13a binds to its cognate crRNA with high affinity (Supplementary Fig. S4a) through an extensive network of conserved sugar-phosphate and nucleobase interactions within a cavity formed by the NTD and Helical-1 domains (Fig. 1d; Fig. 2b; Supplementary Fig. S3a). The 5' handle of LbaCas13a's cognate crRNA is highly compact, as the loop (A(-18)-A(-11)) is condensed into a helical stack (Fig. 2b–d). Only A(-14) is extruded from the cavity and disordered in the solvent (Fig. 2b; Supplementary Fig. S1c). This conformation is in stark contrast to the structure of U-cleaving LshCas13a's crRNA, in which A(-13), A(-15), U(-17) and A(-18) are flipped out of the loop (Fig. 2b).

The 5' handle makes both structure- and sequence-specific contacts with LbaCas13a (Fig. 2c, d, f; Supplementary Fig. S3a). In LbaCas13a, the loop is stabilized by the arrangement of the purines into a quadruple and triple base stack on either side of the single extruded nucleotide, A(-14). The quadruple π -stack (A(-11)-A(-15)) is extended to include Y376 of Helical-1 and is stabilized by base-specific interactions with R369, E410, and E406 (Fig. 2c). Notably, the nucleobases involved in these interactions, G(-12) and A(-15), are strictly conserved within the Type VI-A family (Fig. 2a). The equivalent nucleotides in the Lsh-crRNA (G(-15) and A(-18)) make no base-specific contacts with LshCas13a, consistent with our previous observation that LbaCas13a and LshCas13a cannot functionally exchange crRNA¹⁴. Parallel to the quadruple base stack, nucleotides G(-16)-A(-18) stack between the NTD and Helical-1 domain, forming a triple base stack that is stabilized by R270 hydrogen bonding to backbone phosphates and G(-16) (Fig. 2d). The close proximity of the two sets of stacking nucleotides is further stabilized by a hydrogen bond between the ribose 2'-hydroxyl of G(-12) and nucleobase N3 of A(-17), another contact unique to the compact loop of LbaCas13a.

Beyond stabilizing the crRNA loop, Helical-1 also positions the 5' flank of the stem-loop in a shallow, surface-exposed groove at the interface with HEPN2 (Fig. 1d; Fig. 2e). crRNAs from the A-cleaving subfamily maintain a 5-nt 5' flank, which wraps around the exterior of LbaCas13a, with A(-25) and G(-26) stacking with F1300 and F422, respectively (Fig. 2e). Upstream of the 3' flank, Lba crRNA contains a two-nucleotide bulge, neighboring an A-U base pair that is invariant across the direct repeats of the Type VI-A family. In contrast, the identity of the bulged bases varies as a function of subfamily (Fig. 2a), suggesting that this portion of the sequence may be a crucial feature for crRNA recognition among the two subfamilies. Consistent with this hypothesis, the AA 3'-bulge observed in LbaCas13a (A(-6)-A(-5)) is read sequence-specifically (Fig. 2f; Supplementary Fig. S3a). A(-6) engages in a conserved pocket formed by HEPN1-II and Helical-2, where it stacks with Y928

ordering the nucleobase N7 and amine to hydrogen bond with E921 and Q927, respectively. A(-5) is buried in a pocket formed at the interface of the NTD, Helical-1, and HEPN1-I domains, where it interacts with the backbone carbonyl and side-chain hydroxyl of T21 (Fig. 2f). The set of contacts that recognize A(-6) in LbaCas13a closely resemble those reading out the equivalent A(-8) in LshCas13a¹⁶. In contrast, the second nucleotide of the AC-bulge in LshCas13a (C(-7)) engages in a nucleobase-specific pocket, suggesting the A-cleaving subfamily has diverged to allow for adenosine at this position.

While the REC lobe confers crRNA 5' handle specificity in both U- and A-cleaving Cas13a subfamilies, the landscape of protein-RNA interactions is markedly different. Our structure has revealed differences in crRNA conformation that could not be predicted through simple RNA-folding algorithms. The structure- and sequence-specific contacts observed in LbaCas13a serve to rationalize the previous finding that LbaCas13a cannot effectively utilize non-cognate crRNA from the U-cleaving subfamily¹⁴.

Spacer recognition and activation of LbaCas13a

Cas13a-crRNA complexes show no general RNase activity in the absence of a complementary ssRNA-activator, suggesting that the enzyme is able to achieve complete conformational inhibition until the activator is bound. The binary LbaCas13-crRNA structure represents the target search complex, allowing us to understand the structural constraints on both target identification and HEPN nuclease activation.

We observed unambiguous density for a contiguous stretch of 13 spacer nucleotides immediately proximal to the repeat (C(1)-G(13)) (Fig. 3a). The remaining 11 spacer nucleotides, while present in the crystal (Supplementary Fig. S1b), were disordered in the structure (Supplementary Fig. S1c). The repeat-proximal spacer adopts a distorted U-turn conformation in a pocket between NUC1 and NUC2 (Fig. 3b). Several sugar-phosphate interactions stabilize the highly-distorted RNA conformation within the NUC lobe (Supplementary Fig. S3a). While the discontinuous spacer nucleotides within LshCas13a appear to follow a similar trajectory, our structure provides a more holistic view of spacer orientation within the NUC lobe. The crystal structure of LshCas13a also revealed pre-ordered A-form spacer nucleotides bound at the surface of the NTD¹⁶, which we did not observe in LbaCas13a.

The conformation of the LbaCas13a spacer sequence led us to wonder if spacer length would dramatically impact the HEPN nuclease activity of LbaCas13a. Other homologs have demonstrated HEPN nuclease activation with a variety of spacer-lengths, ranging from 20–28 nucleotides^{10,17}. We did not observe a significant effect of spacer length on rates of LbaCas13a *trans*-ssRNA cleavage across this range (Supplementary Fig. S4b–c). We solved an additional structure of LbaCas13a complexed with a crRNA containing a 20-nt spacer (Table 1; Supplementary Fig. S1b). While the overall protein structure was identical to the 24-nt spacer containing complex, we observed disorder and partial occupancy of the crRNA spacer within the NUC lobe of the 20-nt spacer containing complex (Supplementary Fig. S1d). These observations suggest that LbaCas13a accommodates a range of spacer lengths, sequence identities, and conformations within the spacer cavity, consistent with its role as an adaptive RNA-guided immune system.

We examined the entirety of the bound spacer within LbaCas13a to identify interactions between the NUC lobe and crRNA spacer. The HEPN domains, Helical-2 and Helical-3 domains make a number of conserved contacts with the sugar-phosphate backbone of the spacer (Fig. 3c; Supplementary Fig. S3a–c). Notably, the 3' end of the spacer (C(11)-G(13)) emerges from the NUC lobe, where it adopts an A-form conformation as C(11) stacks with F1293 and F1338 of HEPN2, effectively gating access to the proximal spacer sequence that is sandwiched within the NUC lobe (Fig. 3c). The nucleotides emerging from the NUC lobe adopt a similar conformation in LshCas13a and in our second structure (20nt-spacer) of LbaCas13a (Fig. 3c; Supplementary Fig. S1d–e). Additionally, there are two highly conserved pockets that extensively contact the sugar-phosphate backbone around spacer nucleotides A(6) and A(8), rendering the nucleobases solvent inaccessible (Supplementary Fig. S3b–c). These structural observations suggest that the Cas13a-crRNA complex orders the repeat-proximal spacer into a distorted U-turn while conformationally gating HEPN nuclease activation through an extensive network of interactions with the sugar-phosphate backbone. Further biochemical and structural studies will be required to determine how the spacer rearranges upon activator-binding and how this conformational change triggers Cas13a HEPN domain activation.

We also sought to understand how crRNA-bound LbaCas13a is competent for target search but not active for *trans*-ssRNA cleavage. Evidence from both biochemical and structural experiments has suggested that U-cleaving Cas13a enzymes are dependent on the formation of a composite active-site comprised of two RX₄H motifs, one contributed by each HEPN domain^{8,10,16,17}. In agreement with the catalytic requirements of the U-cleaving subfamily, double mutation of the conserved arginine and histidine within either HEPN1 (R600, H605) or HEPN2 (R1243, H1248) abolished general RNase activity of LbaCas13a (Fig. 3d; Supplementary Fig. 4e, f). In the LbaCas13a structure, the HEPN1 motif adopts a conformation in which α 2 of HEPN1-I is distorted, burying H605 of the RX₄H motif distant from the putative active-site beneath a loop of HEPN2 (Fig. 3e). Given this remote and solvent inaccessible positioning, we questioned whether H605 participates in HEPN nuclease activity. Similar to double mutations in HEPN1 or HEPN2, the single H605A substitution was sufficient to render LbaCas13a catalytically inactive (Fig. 3d), suggesting that activation of the enzyme requires H605 to join the surface-exposed HEPN motif. Overall, these data demonstrate that the HEPN nuclease remains inactive prior to ssRNA-activator binding due to the crRNA-assisted separation of HEPN active site residues. These data extend the previous mechanistic understanding gained from the LshCas13a structure, where it was observed that the HEPN domains were surface exposed to form a composite active site¹⁶. Activator binding must induce a synergistic conformational change involving the release of the spacer from the NUC lobe cavity and accommodation of the activator-spacer RNA duplex, similar to the target RNA binding mechanism observed in human Ago2²³.

Active site for Cas13a crRNA maturation

Pre-crRNA processing is broadly conserved within the Cas13a family, yet despite extensive mutagenesis studies, the precise active-site residues and chemical mechanism are unknown^{10,14,16}. Our binary LbaCas13a-crRNA structure represents the product-bound state of the

pre-crRNA processing reaction, prompting us to examine the mature crRNA 5'-terminus for insights into the catalytic mechanism. The structure revealed that the 5'-flank (C(-24)-A(-28)) is directed away from the core of the enzyme and into a surface-exposed groove formed by the Helical-1 and HEPN2 domains (Fig. 4a). Both Helical-1 and HEPN2 extensively interact with the sugar-phosphate backbone of the 5'-flank, stabilizing the crRNA in the product-bound state (Supplementary Fig. S3a). The residues within LbuCas13a whose mutation results in processing defects are predicted by conservation to line this processing groove between Helical-1 and HEPN2 (Supplementary Fig. S5). The 5' terminal nucleotide within the LbaCas13a structure, A(-28), has a well-resolved 5'-hydroxyl that is surrounded by H328, K435, and K1320, amino acids that are strictly conserved within the Cas13a A-cleaving subfamily (Fig. 4a; Supplementary Fig. S3a, Supplementary Fig. S5).

To test the involvement of H328, K435, and K1320 in crRNA maturation, we substituted alanine at these positions and assayed each point mutant's capacity for pre-crRNA cleavage. All three single point mutants were completely inactive for pre-crRNA processing, confirming the role of H328, K435 and K1320 in catalysis of crRNA maturation (Fig. 4b; Supplementary Fig. S4d). Further biochemical testing of additional residues near A(-28) revealed that alanine substitutions at K432, D1268, or K1305 completely ablate activity, while mutations of W325 or N1232 modestly impact processing (Fig 4b; Supplementary Fig. S4d). To confirm that the observed mutant phenotypes are catalytic deficiencies and not substrate binding defects, we assayed mutant HEPN-nuclease activity and binding affinity of a pre-crRNA mimic substrate. With the exception of D1268A, the processing mutants maintained near wild-type levels of ssRNA *trans*-cleavage activity (Supplementary Fig. S4e-f). Furthermore, all of the catalytically implicated LbaCas13a mutants retained wild-type binding affinity for both the pre-crRNA mimic and the mature crRNA (Supplementary Fig. S4g-i).

These structural and biochemical observations are consistent with crRNA processing occurring via an acid-base mechanism, where the reaction proceeds through a cation metal-independent pathway in which the 2'-hydroxyl nucleophilically attacks the scissile phosphate in the 3' position. To assess the role of divalent cations in pre-crRNA processing, we performed processing reactions in the presence of increasing concentrations of the metal chelator EDTA and observed minimal impacts on LbaCas13a processing activity (Fig. 4c; Supplementary Fig. S4j). To confirm the role of the 2'-hydroxyl of G(-29), we assayed the ability of LbaCas13a to process a pre-crRNA substrate in which the catalytic ribonucleotide is substituted for a 2'-deoxynucleotide (dG(-29) substrate). LbaCas13a was unable to cleave this pre-crRNA mimic substrate (Fig. 4f), providing biochemical evidence for the metal-independent acid-base mechanism of pre-crRNA processing.

To provide support for this model of crRNA processing, we crystallized the crRNA-processing deficient LbaCas13a H328A with a pre-crRNA substrate bearing two nucleotides 5' to the scissile phosphate (Table1; Fig. 4d) Wild-type LbaCas13a can process this truncated pre-crRNA (Supplementary Fig. S4k), suggesting that this structure represents the pre-catalytic, substrate-bound state of crRNA processing. The structure revealed that K435 and K1320 are positioned around the scissile phosphate, while W325 and N1232 stabilize a distorted C2'-endo conformation of the G(-29) ribose. Furthermore, modeling of H328 into

the mutant structure suggests that it would be positioned to contact the scissile phosphate. Interestingly, we did not observe any of the biochemically implicated residues within hydrogen-bonding distance of the ribose 2'-hydroxyl. The pre-crRNA-bound structure revealed that the 2'-hydroxyl of G(-29) contacts N1232 and a single water molecule that is coordinated by HEPN2 residues K1305 and K1320. These structural observations led us to hypothesize that the G(-29) 2'-hydroxyl is deprotonated by an activated water. Consistent with this hypothesis, K1305 is flanked by two carboxylate moieties (D1268 and E1235) that may enable it to act as a general base to activate the coordinated water.

Together these data suggest a model for LbaCas13a-mediated crRNA processing in which conserved residues within the pre-crRNA processing groove between the Helical-1 and HEPN2 domains form an acid-base catalytic center (Fig. 4e). LbaCas13a binds to its cognate pre-crRNA, positioning the 5'-flank within the processing groove where W325 and N1232 stabilize the ribose of G(-29) in a distorted C2'-endo conformation. This coordination sets up the ribose 2'-hydroxyl for nucleophilic attack on the scissile phosphate, at which point K1305, an activated water, K1320, K435 and H328 participate in proton transfer to facilitate the formation of a 2'-3'-cyclic phosphate on G(-29), leaving behind a mature crRNA with a ribose 5'-hydroxyl on A(-28).

DISCUSSION

The signature proteins of Type VI-A CRISPR-Cas systems, Cas13a, are a remarkably diverse family of RNA-guided enzymes that degrade ssRNA non-specifically upon binding a spacer-complementary ssRNA-activator. In this work, we present high-resolution structures of the LbaCas13a:crRNA complex, revealing the active site for pre-crRNA processing and suggesting a structural gating mechanism of RNA-guided HEPN nuclease activity. We also uncovered the key conformational differences between two divergent Cas13a subfamilies, highlighting the molecular basis for orthogonal crRNA preferences. Finally, this study reveals that Cas13a ssRNA targeting activity is constrained during target search by both crRNA spacer conformation and HEPN domain arrangement.

Initial studies determined that residues important for pre-crRNA processing by two Cas13a homologs, LbuCas13a¹⁰ and LshCas13a¹⁶, are located in the groove between the Helical-1 and HEPN2 domains. Our study extends this work by establishing that the active site for pre-crRNA processing by all A-cleaving Cas13a homologs is in the Helical-1/HEPN2 interface based on structural, biochemical and phylogenetic data. Protein sequence divergence and differing sites of cleavage within pre-crRNA preclude direct comparison to all of the U-cleaving Cas13a subfamily members¹⁴. Nonetheless, biochemical evidence suggests that LbuCas13a pre-crRNA processing is also metal ion-independent and likely occurs in an active site located between the Helical-1 and HEPN2 domains^{10,14}. These results are consistent with our identification of a conserved RNA processing groove that likely serves to stabilize the crRNA backbone.

After associating with its crRNA, the Cas13a:crRNA complex is competent for target surveillance. The high-resolution structures presented in this paper reveal conserved contacts between the spacer and the two halves of the NUC lobe, suggesting that these regions may

function in conformational sensing of ssRNA-activator binding. The repeat-proximal portion of the spacer is highly distorted and sequestered within the core of the enzyme, making it unlikely that this pocket could accommodate a complementary activator RNA without significant conformational rearrangements. This contrasts with other RNA-guided nuclease complexes, including Cas9 and Argonaute, which pre-order their guides within an extended but accessible cavity^{24,25}. Due to the anchoring of the crRNA 5' handle within the REC lobe and the U-turn conformation of the spacer, we expect that the activator-bound enzyme may contain distortions from a canonical double helix, similar to the spacer:target duplex observed in Type III Cmr RNA-targeting systems²⁶. We propose that both Cas13a and the distorted crRNA spacer must undergo a concerted conformational change upon ssRNA-activator association that drives HEPN domain dimerization, forming a composite active site and activating Cas13a for ssRNA cleavage.

Cas13a represents a novel paradigm within RNA-guided nucleases where the ordered region of the target-complementary sequence is sequestered within the enzyme, with disordered regions of the guide RNA exposed to solvent. Other RNA-guided nucleases, including the Argonaute family and Cas9, utilize a seed region within their guides for initial nucleic-acid recognition to direct target-binding into a pre-ordered A- or B-form guide^{27,28}. The pre-organization of the seed sequence accelerates target search and mismatch discrimination by decreasing the entropic cost of target binding²⁹. Cas13a is not following this model for target search, as the solvent-accessible crRNA regions are disordered and the ordered crRNA regions are incompatible with duplex formation. Due to the kinked and inaccessible spacer nucleotides, complementary ssRNA-activator binding can only occur once the system overcomes this additional energetic barrier, raising the question of what energetic parameter drives ternary complex formation.

The Cas13a enzyme family continues to be developed as a platform for RNA detection and programmable RNA binding^{13,14}. Bioengineering of Cas13a will require a complete understanding of how the enzyme carries out target search and is subsequently activated to become a general RNase. Our high-resolution target surveillance structure provides key details about crRNA recognition, processing and spacer ordering that will advance the development of LbaCas13a as valuable tool for RNA detection.

METHODS

LbaCas13a protein production and purification

The expression and purification of *Lachnospiraceae bacterium* NK4A179 Cas13a (LbaCas13a) was carried out as described elsewhere¹⁴ with modifications, summarized here: His₆-MBP-TEV-tagged Cas13a was prepared in *E. coli* Rosetta2 (DE3) grown in TB at 37°C. At an OD₆₀₀ of 0.4–0.5, cultures were cooled on ice for 15 minutes prior to induction with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and expression overnight at 16°C. Soluble His₆-MBP-TEV Cas13a was loaded onto a 5 mL HiTrap NiNTA column (GE Healthcare) and eluted over a linear imidazole (0.01–0.3 M) via FPLC (ÄKTA Pure). After overnight dialysis and TEV digestion, the eluted LbaCas13a was further purified by ion exchange (5 mL HiTrap SP, GE Healthcare) and size-exclusion chromatography (S200 16/60, GE Healthcare) with 2 mM TCEP supplemented into the gel filtration buffer.

***In vitro* transcription and purification of RNA**

For biochemical experiments, RNA was transcribed and radiolabeled as described previously¹⁴. For crystallization, pre-crRNA was transcribed *in vitro* from a PCR-amplified double-stranded DNA template encoding a hepatitis delta virus (HDV) ribozyme 3' to the pre-crRNA sequence. Transcriptions were carried out as described previously¹⁰ with the following modifications: pre-crRNAs were transcribed at 37°C overnight, followed by treatment with DNase I and 5 mM MgCl₂ (37°C, 1 hr) to quench the reaction and drive ribozyme cleavage. Before complexing with LbaCas13a, pre-crRNA was annealed in 1X annealing buffer (10 mM Na-HEPES pH 7.4, 30 mM KCl, 1.5 mM MgCl₂) by heating at 75°C for 5 min followed by rapid cooling on ice.

LbaCas13a:pre-crRNA complex formation

For crystallization, the LbaCas13a:crRNA or LbaCas13a (H328A) pre-crRNA complex was reconstituted *in vitro* by incubating purified LbaCas13a protein with pre-crRNA at a molar ratio of 1:1.3 at 37°C for 1 hr in complexing buffer (20 mM Na-HEPES pH 7.0, 200 mM KCl, 1 mM TCEP). The complex was purified by size-exclusion chromatography (S200 10/300 Increase, GE Healthcare) in complexing buffer and concentrated using a 10 kDa Centricon (Thermo Fisher) before immediate use in crystallization experiments. The purity and integrity of protein and RNA were assessed using SDS-PAGE (Coomassie blue staining) and 15% (v/v) TBE-urea-polyacrylamide gel electrophoresis (SYBR Gold staining), respectively (Supplementary Fig. S1b).

LbaCas13a crystallization and data collection

Initial screening was carried out with JCSG Core Suites (Qiagen) in 96-well sitting drop vapor diffusion format (Intelli-plate, Hampton Research) at 293 ± 1 K. Diffraction-quality crystals of the LbaCas13a:crRNA complex (20-nt and 24-nt containing spacer) ($A_{280}=4.0$) and LbaCas13a:pre-crRNA complex (24-nt containing spacer) ($A_{280}=5.7$) grew in 0.2 M ammonium iodide and 20% (w/v) PEG 3,350. Crystals were cryoprotected in 10–15% (v/v) glycerol, and high-resolution diffraction data were collected at the Advanced Light Source (ALS) beam line 8.3.1 on a Pilatus3 S 6M (Dectris) detector under cryogenic conditions. To produce isomorphous crystals for phasing by native single-anomalous dispersion (SAD), sitting drop vapor diffusion experiments containing 2 μ L purified LbaCas13a:crRNA complex (24-nt containing spacer) complex ($A_{280}=4.0$) and 2 μ L reservoir solution (0.2 M ammonium iodide, 20–25% (w/v) PEG 3,350) were prepared in 24-well Cryschem plates (Hampton Research). A total of 52 datasets were collected from 26 crystals (cryoprotected in 10% (v/v) glycerol) under cryogenic conditions at 6.0 keV (ALS beam line 8.3.1, Pilatus3 S 6M). Each dataset covered 360° of crystal rotation divided into 0.2° images collected in 45° inverse-beam wedges at 5 Hz. To minimize pixel readout error, the detector was moved by 10 mm before collecting a second 360°-pass from the same position of each crystal.

Structure determination by native SAD and model refinement

High-resolution data collected from LbaCas13a crystals at 11.1 keV were processed and scaled in *XDS*³⁰ before merging in *AIMLESS*^{31,32}. After processing with *XDS*, each SAD dataset was compared to every other dataset after applying each of the 27 possible re-

indexing operations found by *OTHERCELL*³¹, and then computing an isomorphous R-factor with a 4 Å resolution cut-off using *SCALEIT*³¹. Pairs of datasets agreeing to better than 20% were grouped and merged using *XSCALE*³⁰ producing a final cluster containing 20 wedges in the space group C2 (data statistics summarized in Table 1). The merged anomalous data were prepared for substructure search in *SHELXC*³³, and input into *SHELXD* set to search for 65 sites using a high-resolution cutoff of 3.5 Å. Nine solutions were found after 25,000 trials and each solution was input separately into *SHELXE*. The correct substructure solution was found to contain a total of 115 sites, 32 of which were correct as determined using *PHENIX.emma*³⁴. A readily interpretable map (CC 25%) was obtained after 30 cycles of density modification and model building in *SHELXE*. *PHENIX.AutoBuild*³⁵ was used to extend the initial α -helical model, complemented with manual model-building in *COOT*³⁶ and RNA-modelling with *RCrane*³⁷. The atomic models were completed by iterative building and refinement in *COOT* and *PHENIX.refine*³⁸ against the high-resolution data using the $2mF_o-DF_c$, mF_o-DF_c , anomalous Fourier difference and $2mF_o-DF_c$ composite omit³⁹ maps. The final models for LbaCas13a:crRNA (24-nt spacer), LbaCas13a:crRNA (20-nt spacer), and LbaCas13a(H328A):pre-crRNA (24-nt spacer) were validated in *MOLPROBITY*⁴⁰ and submitted to the Protein Data Bank (PDB) under the accession codes 5W1H, 5W1I, and 5WLH respectively. All figures were generated in *PyMOL* (PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC).

Radiolabeled crRNA maturation assays

Pre-crRNA processing assays were performed as previously described¹⁴. Briefly, 100 nM LbaCas13a was incubated with <1 nM 5'-radiolabeled pre-crRNA substrates at 37°C in processing buffer (20 mM HEPES-Na pH 6.8, 50 mM KCl, 5 mM MgCl₂, 10 µg/mL BSA, 100 µg/mL tRNA, 0.01% Igepal CA-630, and 5% glycerol). Reactions were quenched (100% formamide, 0.025% bromophenol blue, and 200 µg/mL heparin), denatured at 95°C for 5 min and resolved by 15% denaturing PAGE (0.5x TBE buffer). All bands were visualized by phosphorimaging (Typhoon, GE Healthcare) and quantified with ImageQuant (GE Healthcare). The percent cleavage was determined as the ratio of the intensity of the product band to the total intensity of both the product and uncleaved pre-crRNA bands, and normalized for background within each measured substrate. For clarity, in some figure panels the percentage of uncleaved substrates is presented (calculated as 100-%cleaved).

Fluorescent ssRNA nuclease assays

Target cleavage assays were performed as previously described with minimal modification¹⁴. Briefly, 100 nM LbaCas13a was complexed with 50 nM pre-crRNAs at 37°C in processing buffer for 30–60 mins. Alternatively, cleavage buffer (20 mM HEPES-Na pH 6.8, 50 mM KCl, 5 mM MgCl₂) was used for reactions instead of processing buffer as noted in the figure legends, resulting in less fluorescent signal generated. Generally, 150 nM RNase Alert reporter (IDT) and 10 nM of ssRNA-activator were added to initiate the reaction. Reactions were incubated in a fluorescence plate reader (Tecan Infinite Pro F2000) for 60 min at 37°C, with fluorescence measurements taken every 5 min (λ_{ex} : 485 nm; λ_{em} : 535 nm). Background corrected values were calculated by subtracting signal in the negative control containing no activating RNA. For endpoint analyzes, the background corrected fluorescence value from the 60 min time point is presented (mean $\pm$ st. dev., n= 3). Apparent

rates were calculated according to a single-exponential decay using Prism7 (GraphPad) fitted to the entire curve, and calculated rates were plotted with their associated standard deviations (n=3).

Filter-binding assays

Filter-binding assays were carried out as previously described¹⁰. Briefly, Cas13a and radiolabeled crRNA were incubated for 1 hr at 37°C in RNA-processing buffer (20 mM HEPES-Na pH 6.8, 50 mM KCl, 5 mM MgCl₂, 10 µg/mL BSA, 100 µg/mL yeast tRNA, 0.01% Igepal CA-630 and 5% glycerol). Tufryn, Protran and Hybond-N+ membranes were assembled onto a dot-blot apparatus in the order listed. The membranes were washed twice with 50 µL cleavage buffer (20 mM HEPES-Na pH 6.8, 50 mM KCl, 5 mM MgCl₂, and 5% glycerol) before the sample was applied to the membranes. Membranes were then washed with 50 µL cleavage buffer, dried, and visualized by phosphorimaging. Data were quantified with ImageQuant TL Software (GE Healthcare) and fit to a binding isotherm using Prism7 (GraphPad). All experiments were carried out in triplicate.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Nan Ma and Kaihong Zhou for technical assistance, Christine L. Gee for assistance with refinement, and members of the Doudna laboratory for helpful discussions. G.J.K. acknowledges support from the Howard Hughes Medical Institute. This work was supported in part by a Frontiers Science award from the Paul Allen Institute to J.A.D. and the National Science Foundation (MCB-1244557 to J.A.D.). J.A.D. is an Investigator of the Howard Hughes Medical Institute. J.A.D. is a co-founder of Caribou Biosciences, Inc., Editas Medicine, and Intellia Therapeutics.

References

1. Dy RL, Richter C, Salmond GP, Fineran PC. Remarkable Mechanisms in Microbes to Resist Phage Infections. *Annu Rev Virol*. 2014; 1:307–31. [PubMed: 26958724]
2. Barrangou R, Marraffini LA. CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity. *Mol Cell*. 2014; 54:234–44. [PubMed: 24766887]
3. Marraffini LA. CRISPR-Cas immunity in prokaryotes. *Nature*. 2015; 526:55–61. [PubMed: 26432244]
4. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. *Cell*. 2014; 157:1262–78. [PubMed: 24906146]
5. Wright AV, Nunez JK, Doudna JA. Biology and Applications of CRISPR Systems: Harnessing Nature's Toolbox for Genome Engineering. *Cell*. 2016; 164:29–44. [PubMed: 26771484]
6. Barrangou R, Doudna JA. Applications of CRISPR technologies in research and beyond. *Nat Biotechnol*. 2016; 34:933–941. [PubMed: 27606440]
7. O'Connell MR, et al. Programmable RNA recognition and cleavage by CRISPR/Cas9. *Nature*. 2014; 516:263–6. [PubMed: 25274302]
8. Shmakov S, et al. Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems. *Molecular Cell*. 2015; 60:385–397. [PubMed: 26593719]
9. Nelles DA, et al. Programmable RNA Tracking in Live Cells with CRISPR/Cas9. *Cell*. 2016; 165:488–96. [PubMed: 26997482]
10. East-Seletsky A, et al. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. *Nature*. 2016

11. Shmakov S, et al. Diversity and evolution of class 2 CRISPR-Cas systems. *Nat Rev Microbiol*. 2017
12. Smargon AA, et al. Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28. *Mol Cell*. 2017
13. Gootenberg JS, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. *Science*. 2017; 356:438–442. [PubMed: 28408723]
14. East-Seletsky A, O'Connell MR, Burstein D, Knott GJ, Doudna JA. RNA Targeting by Functionally Orthogonal Type VI-A CRISPR-Cas Enzymes. *Mol Cell*. 2017; 66:373–383 e3. [PubMed: 28475872]
15. Mojica FJ, Diez-Villasenor C, Garcia-Martinez J, Almendros C. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. *Microbiology*. 2009; 155:733–40. [PubMed: 19246744]
16. Liu L, et al. Two Distant Catalytic Sites Are Responsible for C2c2 RNase Activities. *Cell*. 2017; 168:121–134 e12. [PubMed: 28086085]
17. Abudayyeh OO, et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. *Science*. 2016; 353:557.
18. Haurwitz RE, Jinek M, Wiedenheft B, Zhou K, Doudna JA. Sequence- and structure-specific RNA processing by a CRISPR endonuclease. *Science*. 2010; 329:1355–8. [PubMed: 20829488]
19. Sternberg SH, Haurwitz RE, Doudna JA. Mechanism of substrate selection by a highly specific CRISPR endoribonuclease. *RNA*. 2012; 18:661–72. [PubMed: 22345129]
20. Li H. Structural Principles of CRISPR RNA Processing. *Structure*. 2015; 23:13–20. [PubMed: 25435327]
21. Hochstrasser ML, Doudna JA. Cutting it close: CRISPR-associated endoribonuclease structure and function. *Trends Biochem Sci*. 2015; 40:58–66. [PubMed: 25468820]
22. Charpentier E, Richter H, van der Oost J, White MF. Biogenesis pathways of RNA guides in archaeal and bacterial CRISPR-Cas adaptive immunity. *FEMS Microbiol Rev*. 2015; 39:428–41. [PubMed: 25994611]
23. Schirle NT, Sheu-Gruttadauria J, MacRae IJ. Structural basis for microRNA targeting. *Science*. 2014; 346:608–13. [PubMed: 25359968]
24. Jiang F, Doudna JA. The structural biology of CRISPR-Cas systems. *Curr Opin Struct Biol*. 2015; 30:100–11. [PubMed: 25723899]
25. Nakanishi K. Anatomy of RISC: how do small RNAs and chaperones activate Argonaute proteins? *Wiley Interdiscip Rev RNA*. 2016; 7:637–60. [PubMed: 27184117]
26. Osawa T, Inanaga H, Sato C, Numata T. Crystal structure of the CRISPR-Cas RNA silencing Cmr complex bound to a target analog. *Mol Cell*. 2015; 58:418–30. [PubMed: 25921071]
27. Parker JS, Parizotto EA, Wang M, Roe SM, Barford D. Enhancement of the seed-target recognition step in RNA silencing by a PIWI/MID domain protein. *Mol Cell*. 2009; 33:204–14. [PubMed: 19187762]
28. Jiang F, Zhou K, Ma L, Gressel S, Doudna JA. STRUCTURAL BIOLOGY. A Cas9-guide RNA complex preorganized for target DNA recognition. *Science*. 2015; 348:1477–81. [PubMed: 26113724]
29. Salomon WE, Jolly SM, Moore MJ, Zamore PD, Serebrov V. Single-Molecule Imaging Reveals that Argonaute Reshapes the Binding Properties of Its Nucleic Acid Guides. *Cell*. 2015; 162:84–95. [PubMed: 26140592]
30. Kabsch W. Xds. *Acta Crystallogr D Biol Crystallogr*. 2010; 66:125–32. [PubMed: 20124692]
31. Winn MD, et al. Overview of the CCP4 suite and current developments. *Acta Crystallogr D Biol Crystallogr*. 2011; 67:235–42. [PubMed: 21460441]
32. Evans PR, Murshudov GN. How good are my data and what is the resolution? *Acta Crystallogr D Biol Crystallogr*. 2013; 69:1204–14. [PubMed: 23793146]
33. Powell HR. The Rossmann Fourier autoindexing algorithm in MOSFLM. *Acta Crystallogr D Biol Crystallogr*. 1999; 55:1690–5. [PubMed: 10531518]
34. Adams PD, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr*. 2010; 66:213–21. [PubMed: 20124702]

35. Terwilliger TC, et al. Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. *Acta Crystallogr D Biol Crystallogr*. 2008; 64:61–9. [PubMed: 18094468]
36. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. *Acta Crystallogr D Biol Crystallogr*. 2010; 66:486–501. [PubMed: 20383002]
37. Keating KS, Pyle AM. Semiautomated model building for RNA crystallography using a directed rotameric approach. *Proc Natl Acad Sci U S A*. 2010; 107:8177–82. [PubMed: 20404211]
38. Afonine PV, et al. Towards automated crystallographic structure refinement with phenix.refine. *Acta Crystallogr D Biol Crystallogr*. 2012; 68:352–67. [PubMed: 22505256]
39. Terwilliger TC, et al. Iterative-build OMIT maps: map improvement by iterative model building and refinement without model bias. *Acta Crystallogr D Biol Crystallogr*. 2008; 64:515–24. [PubMed: 18453687]
40. Chen VB, et al. MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr D Biol Crystallogr*. 2010; 66:12–21. [PubMed: 20057044]

Figure 1. Overall structure of the LbaCas13a:crRNA complex

a, Phylogenetic tree of all Cas13a family members with colored circles highlighting the A- and U-cleaving subfamilies (adapted from ¹⁴). The homolog described in this study, LbaCas13a, is highlighted in yellow. **b**, Schematic representation of the crRNA repeat scaffold crystallized in this study. Nucleotides at the 5' and 3' end that were disordered in the structure are shown in semitransparent text. The ribose and nucleobase of G(14) were disordered. Only the phosphate of G(14) was modeled in the structure and is represented here as a dashed circle. **c**, Domain organization schematic of LbaCas13a shown with the REC, NUC, NUC1, and NUC2 lobes annotated. The color code used is consistent throughout the manuscript. **d**, Two views of the LbaCas13a:crRNA complex are shown related by a 180° rotation as cartoon (top) or surface (bottom) representations. The crRNA backbone is shown in orange.

Figure 2. Structure and recognition of the crRNA 5' handle

a, Multiple sequence alignment of select type VI-A Cas13a crRNA 5' handles representing both subfamilies adapted from ¹⁴. Nucleotides conserved across all Cas13a homologs, amongst just the U-cleaving, or A-cleaving subfamily are shown in grey, teal or purple respectively. The sites of pre-crRNA processing for each Cas13a homolog are noted by red arrows. LbaCas13a, is highlighted in yellow with the repeat nucleotides numbered negatively from the start of the spacer. **b**, Side by side comparison of the crRNA crystallized in this study (LbaCas13a, left) and previously ¹⁶ (LshCas13a, right). **c–f**, Highlights of specific interactions between the crRNA 5' handle and LbaCas13a. Purine stacks within the loop region of the 5' handle interacting with Helical-1 and the NTD (**c–d**). Residues involved in conserved contacts between LbaCa13a and the crRNA loop are shown as sticks, with hydrogen-bonding interactions denoted by dashed lines. Binding of the 5' flank (A(-28)-U(-24)) of LbaCas13a within the shallow Helical-1/HEPN2 groove via F422 and F1300 stacking with G(-26) and A(-25) respectively (**e**), and sequence-specific recognition of the dinucleotide 3' AA-bulge (**f**).

Figure 3. Structure and recognition of the crRNA spacer

a, Simulated annealing mF_o-DF_c omit electron density map of the crRNA spacer contoured at 2σ . **b**, Opposing perspectives of the two halves of the NUC lobe that distort the crRNA spacer into a stabilized U-turn conformation. The half of the NUC lobe projecting out of the page is omitted in each image for clarity. **c**, The 3' spacer emerging from the NUC lobe where it interacts with HEPN2. The spacer is shown in cartoon representation (orange) with the A-form nucleobases C(11)-G(13) shown as sticks. The amino acids F1338 and F1293 are shown as sticks stacking with C(11) gating access to the upstream spacer. **d**, Endpoint total fluorescence values for ssRNA-targeting assay by LbaCas13a HEPN mutants (background-corrected mean $\pm$ st. dev, $n=3$). Fitted apparent rates for these reactions are presented in Supplementary Fig. S4e. **e**, View of the composite HEPN nuclease active-site with the catalytic residues (RX₄H) shown in stick representation. Notably, H605 of HEPN1-I is removed from the surface exposed composite site with distances shown.

Figure 4. Structural basis for crRNA maturation by LbaCas13a

a, The pre-crRNA processing groove formed between Helical-1 and HEPN2 domains of wild-type LbaCas13a (left). Close-up view of the pre-crRNA processing site in LbaCas13a (right). The 5'-hydroxyl and amino acids implicated in processing are shown as sticks with hydrogen-bonding interactions denoted by dashed lines. **b**, LbaCas13a-mediated pre-crRNA processing measured under single-turnover conditions for alanine substitutions within the pre-crRNA processing groove. For clarity, 60 min endpoints (mean $\pm$ st. dev, $n=3$) are graphed as the percentage of substrate remaining (uncleaved pre-crRNA). Time course data are plotted and rates calculated in Supplementary Fig. S4. **c**, Bar graph of LbaCas13a-mediated pre-crRNA processing under single-turnover conditions in the presence of EDTA or a modified pre-crRNA dG(-29). Percentage of uncleaved substrate was measured after 60 min (background correct mean $\pm$ st. dev, $n=3$). **d**, Close-up view of the pre-catalytic state of LbaCas13a (H328A) showing the pre-crRNA processing groove formed between Helical-1 and HEPN2 domains. The amino acids surrounding the scissile phosphate between A(-28) and G(-29) are shown as sticks with hydrogen-bonding interactions denoted by dashed lines. H328, marked with an asterisk, is shown in a ball-and-stick representation modeled in the conformation observed in the structure of wild-type LbaCas13a. **e**, Proposed model for acid-base-catalyzed maturation of pre-crRNA by LbaCas13a.

Table 1

Data collection and refinement statistics

	LbaCas13a:crRNA (24-nt spacer) ⁺	LbaCas13a:crRNA (20-nt spacer) ⁺	LbaCas13a:pre-crRNA (24-nt spacer) ⁺	LbaCas13a:crRNA (24-nt spacer) (SAD) [‡]
Data collection				
Space group	C 1 2 1	P 1	C 1 2 1	C 1 2 1
Cell dimensions				
<i>a</i> , <i>b</i> , <i>c</i> (Å)	150.84, 92.21, 115.86	88.78, 89.21, 116.31	150.84, 92.21, 115.86	150.69, 91.45, 115.37
α β γ (°)	90.00, 92.42, 90.00	86.14, 86.97, 66.16	90.00, 92.42, 90.00	90.00, 92.76, 90.00
Resolution (Å)	47.12-1.99 (2.02-1.99) *	48.57-2.20 (2.24-2.20) *	47.11-1.80 (1.86-1.80) *	46.94-3.50 (3.83-3.50) *
<i>R</i> _{merge}	0.079 (0.841)	0.110 (1.060)	0.048 (0.666)	0.406 (0.534) [‡]
<i>I</i> / σ <i>I</i>	15.2 (2.0)	8.6 (1.3)	18.1 (2.2)	36.0 (30.0)
CC (1/2)	0.99 (0.70)	0.996 (0.466)	0.99 (0.77)	0.99 (0.99)
Completeness (%)	98.8 (89.7)	97.5 (96.6)	97.3 (95.3)	100.0 (100.0)
Redundancy	6.9 (6.0)	3.6 (3.7)	5.0 (5.2)	118.6 (120.2)
Refinement				
Resolution (Å)	47.12-1.99 (2.02-1.99)	48.57-2.20 (2.24-2.20)	47.11-1.80 (1.86-1.80) *	
No. reflections	107,256	161,267	142,815	
<i>R</i> _{work} / <i>R</i> _{free}	18.50 / 21.63	19.65 / 23.30	18.59 / 21.85	
No. atoms	12,499	24, 245	12,394	
Protein	11,646	23, 086	11,601	
Ligand/ion	41	16	26	
Water	812	1,143	767	
<i>B</i>-factors				
Protein	36.35	44.31	37.08	
Ligand/ion	56.91	83.97	64.51	
Water	39.68	41.30	37.95	
R.m.s. deviations				
Bond lengths (Å)	0.003	0.002	0.006	
Bond angles (°)	0.482	0.415	0.830	

⁺ A single dataset was scaled and merged for each crystal structure.

[‡] A total of 20 datasets were scaled and merged.

* Values in parentheses are for highest-resolution shell.

[‡] The high *R*_{merge} for the SAD data is due to non-isomorphism between the 20 merged crystals.